Q2042 Tisagenlecleucel car-pos t
Q-Codes
Also known as: Kymriah, tisagenlecleucel, CAR-T
Tisagenlecleucel CAR-positive T-cell therapy, chimeric antigen receptor T-cell immunotherapy for CD19-positive hematologic malignancies.
Clinical Context
Used for relapsed/refractory B-cell acute lymphoblastic leukemia in children and adults, and certain lymphomas. Engineered cells target CD19+ malignancies.
RVU Breakdown
| Work RVU | 0.00 |
| Practice Expense RVU | 0.00 |
| Malpractice RVU | 0.00 |
| Total RVU | 0.00 |
Specialties
Track This Code in RVU Edge
Log procedures, calculate wRVUs, and benchmark against MGMA data — all in one app.
CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.